At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.


French German Italian Portuguese Russian

Treatment Study for Newly Diagnosed High Risk B-Lymphoblastic Leukemia in Patients with Ph-like TKI Sensitive Mutations

Clinical Trial Title: 
A phase III randomized trial for newly diagnosed high risk B-lymphoblastic leukemia (B-ALL) including a stratum evaluating dasatinib (IND#73789, NSC#732517) in patients with Ph-like tyrosine kinase inhibitor (TKI) sensitive mutations.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Mary Lou Schmidt, MD
Clinical Trial Protocol Description: 

To determine if the administration of post-induction age adjusted intrathecal triple chemotherapy on an chemotherapy backbone will  improve 5-year DFS of children with high risk B-ALL compared to age adjusted intrathecal methotrexate.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are more than 365 days old and less than 31 years of age.
  • White blood cell count (WBC) criteria:
    • Are 1 to 9.99 years of age: WBC of 50,000/µL
    • Are 10 to 30.99 years of age: Any WBC
    • Are 1 to 30.99 years of age: Any WBC with:
      • Testicular leukemia
      • CNS leukemia (CNS3)
      • Steroid pretreatment

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Email: 
Contact Phone: 
(312) CANCER-1
Contact Name: 
Rush Cancer Center Clinical Trials Office